Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hua Tu

Showing results (221-230 of 252) with videos related to

Pageof 26
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)Daqing Sun, Zhulun Wang, Mario Cardozo, et al.
Cell|July 17, 2012
Beige adipocytes are a distinct type of thermogenic fat cell in mouse and humanJun Wu, Pontus Boström, Lauren M Sparks, et al.
Science Advances|December 8, 2022
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivoJames A Torchia, Alexander H Tavares, Laura S Carstensen, et al.
Elife|December 15, 2023
Single-cell sequencing highlights heterogeneity and malignant progression in actinic keratosis and cutaneous squamous cell carcinomaDan-Dan Zou, Ya-Zhou Sun, Xin-Jie Li, et al.
The Journal of Biological Chemistry|November 28, 2012
An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoJie Tang, Jiangwen Majeti, Athena Sudom, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 19, 2025
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancerChao Chen, Jie Chen, Jin Huang, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11 beta-HSD1 inhibitorsDustin L McMinn, Yosup Rew, Athena Sudom, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitorsXuelei Yan, Zhulun Wang, Athena Sudom, et al.
Clinical Kidney Journal|January 8, 2024
All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortalityJia-Jin Chen, Tao-Han Lee, George Kuo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2017
Family Aggregation and Heritability of ESRD in Taiwan: A Population-Based StudyHsin Hsu Wu, Chang Fu Kuo, I Jung Li, et al.
Pageof 26

Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)Daqing Sun, Zhulun Wang, Mario Cardozo, et al.
Cell|July 17, 2012
Beige adipocytes are a distinct type of thermogenic fat cell in mouse and humanJun Wu, Pontus Boström, Lauren M Sparks, et al.
Science Advances|December 8, 2022
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivoJames A Torchia, Alexander H Tavares, Laura S Carstensen, et al.
Elife|December 15, 2023
Single-cell sequencing highlights heterogeneity and malignant progression in actinic keratosis and cutaneous squamous cell carcinomaDan-Dan Zou, Ya-Zhou Sun, Xin-Jie Li, et al.
The Journal of Biological Chemistry|November 28, 2012
An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoJie Tang, Jiangwen Majeti, Athena Sudom, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 19, 2025
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancerChao Chen, Jie Chen, Jin Huang, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11 beta-HSD1 inhibitorsDustin L McMinn, Yosup Rew, Athena Sudom, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitorsXuelei Yan, Zhulun Wang, Athena Sudom, et al.
Clinical Kidney Journal|January 8, 2024
All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortalityJia-Jin Chen, Tao-Han Lee, George Kuo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2017
Family Aggregation and Heritability of ESRD in Taiwan: A Population-Based StudyHsin Hsu Wu, Chang Fu Kuo, I Jung Li, et al.
Pageof 26